Clinical trial· 2014
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.
The Journal of clinical investigation
Related molecule only: kisspeptin-54, not kisspeptin-10.
Back to all molecules
Human researchNot FDA-approved
Kisspeptin-10
Kisspeptin decapeptide fragment
Also indexed as: Metastin fragment 45-54
What this evidence does not tell us
Kisspeptin-10 physiology studies must be distinguished from kisspeptin-54 IVF trials. Evidence for the longer form does not automatically apply to this fragment.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
7 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
7 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
Kisspeptin-10 is a ten-amino-acid fragment of the kisspeptin peptide family. The family has an important role in reproductive signaling, but findings from different kisspeptin lengths are not interchangeable.
Mechanism of action
KISS1R / GnRH
Activates KISS1R, influencing hypothalamic GnRH release and downstream LH/FSH secretion; responses depend on physiological context.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Human evidence is still developing
- Limited evidence
- Early research
- Human researchCurrent category
- Human outcomes
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: Kisspeptin-10 physiology studies must be distinguished from kisspeptin-54 IVF trials. Evidence for the longer form does not automatically apply to this fragment.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Human LH-response research exists for kisspeptin-10; the supplied IVF study instead uses kisspeptin-54.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
Reproductive hormone signaling and GnRH/LH responses.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Effects vary by sex and endocrine state. FDA highlights limited safety information and immunogenicity concerns. Reproductive-axis manipulation requires specialist assessment.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Read FDA’s compounding safety informationRegulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Human physiology study· 2011
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
Journal of Clinical Endocrinology & Metabolism
Hormone-response endpoint, not proof of general fertility efficacy.
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.